REGN 411.87 Regeneron Pharmaceuticals $REGN Hit a 52 week high of 414.87 Closing the day 09:44 at 411.87 -3.38 -0.81% With a day low of 411.29 and a total volume of 46,834.
REGN Recent Posts: http://investorshangout.com/Regeneron-Pharmac...EGN-55275/
REGN Regeneron Pharmaceuticals Recent Headline News
Sanofi's Bullish Pipeline Forecast Underwhelms Street
at Investor's Business Daily - 2 mins ago
French big pharma Sanofi laid out its seven-year plan for drug launches, which it says will bring in a cumulative 30 billion euros ($37.6 billion) in their first five years of sales. But Sanofi stock slipped 3% in early trading on the stock market...
NVO: 44.44 (-0.30), MRK: 59.29 (-0.35), LLY: 66.95 (-0.26), SNY: 47.00 (-1.09), REGN: 416.65 (+1.40)
Dupilumab tagged a Breakthrough Therapy for atopic dermatitis
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 7:16AM CST
SNY: 47.00 (-1.09), REGN: 416.65 (+1.40)
Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis
PR Newswire - Thu Nov 20, 12:30AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to dupilumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who are not adequately controlled with topical prescription therapy and/or for whom these treatments are not appropriate. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response. The designation is based on positive results from Phase 1 and 2 clinical trials.
SAN: 8.30 (-0.15), SNY: 47.00 (-1.09), REGN: 416.65 (+1.40)
Regeneron/Bayer's Eylea Gets Japanese Approval for DME - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 3:30PM CST
Regeneron (REGN) announced that the HealthCare segment of Bayer received Japanese approval for Eylea for the treatment of diabetic macular edema.
BIIB: 301.83 (-1.78), AMAG: 35.29 (+0.13), REGN: 416.65 (+1.40)
Positive clinical trial results for alirocumab presented at AHA meeting
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 11:35AM CST
AMGN: 164.11 (+1.47), SNY: 47.00 (-1.09), REGN: 416.65 (+1.40)
Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 10:23AM CST
Regulatory updates from Gilead (GILD) and Regeneron (REGN) and Geron's (GERN) deal with J&J were the highlights last week in the biotech sector.
GILD: 102.55 (+0.21), GERN: 3.18 (+0.07), CLDX: 20.94 (+2.21), CYTR: 2.56 (-0.07), AMGN: 164.11 (+1.47), ABBV: 65.45 (-0.05), REGN: 416.65 (+1.40)
Sanofi and Regeneron Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol
PR Newswire - Wed Nov 19, 7:15AM CST
Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new detailed positive results from six Phase 3 ODYSSEY trials that showed alirocumab significantly reduced low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol). Alirocumab is an investigational fully human monoclonal antibody targeting the protein PCSK9 (proprotein convertase subtilisin/kexin type 9) that is being evaluated for its ability to lower LDL-C.
SAN: 8.30 (-0.15), SNY: 47.00 (-1.09), REGN: 416.65 (+1.40)
Regeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol
PR Newswire - Wed Nov 19, 7:15AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced new detailed positive results from six Phase 3 ODYSSEY trials that showed alirocumab significantly reduced low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol). Alirocumab is an investigational fully human monoclonal antibody targeting the protein PCSK9 (proprotein convertase subtilisin/kexin type 9) that is being evaluated for its ability to lower LDL-C.
SAN: 8.30 (-0.15), SNY: 47.00 (-1.09), REGN: 416.65 (+1.40)
Merck IMPROVEs-IT Causing These Biotechs' Stock Prices to Improve Too
Brian Orelli, The Motley Fool - Motley Fool - Tue Nov 18, 3:00PM CST
Pop quiz: Which one of these drug companies released major positive clinical trial data yesterday? Company Intraday Increase Monday from Friday's Close Merck 1.4% Regeneron Pharmaceuticals 3.3% ...
ESPR: 29.12 (-1.65), MRK: 59.29 (-0.35), REGN: 416.65 (+1.40)
Eylea expands label in Japan
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 8:32AM CST
SNY: 47.00 (-1.09), REGN: 416.65 (+1.40)
Cramer's Mad Money - Globalstar Defends Itself (11/17/14)
SA Editor Miriam Metzinger - Seeking Alpha - Tue Nov 18, 5:37AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday November 17. CEO Interview Jay Monroe, Globalstar (NYSEMKT: GSAT ) Jay Monroe, CEO of Globalstar ( GSAT ) appeared on Mad Money to defend the company...
CST: 43.23 (+0.09), WHR: 181.51 (+1.62), MPC: 95.38 (+1.58), HAL: 49.14 (+0.71), TSN: 43.22 (+0.04), SHW: 240.82 (-0.03), GSAT: 2.64 (-0.03), REGN: 416.65 (+1.40), LULU: 46.65 (+1.05), BHI: 64.23 (+0.72)
Jim Cramer's Top Stock Picks: REGN CST MPC LULU
at The Street - Tue Nov 18, 5:00AM CST
Lululemon is worth a second look now and CST Brands would be a perfect fit for a refiner like Marathon Petroleum.
CST: 43.23 (+0.09), MPC: 95.38 (+1.58), REGN: 416.65 (+1.40), LULU: 46.65 (+1.05)
Regeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Diabetic Macular Edema (DME) in Japan
PR Newswire - Tue Nov 18, 2:05AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for EYLEA® (aflibercept) Injection for diabetic macular edema (DME).
REGN: 416.65 (+1.40)
Jim Cramer's 'Mad Money' Recap: When Bad News Is Really Good News for Us
at The Street - Mon Nov 17, 7:09PM CST
Cramer says this morning's losses and afternoon's gains prove that not all markets need to trade in tandem.
CST: 43.23 (+0.09), BIIB: 301.83 (-1.78), GE: 26.94 (+0.02), NKE: 97.42 (+0.47), HAL: 49.14 (+0.71), TSN: 43.22 (+0.04), GSAT: 2.64 (-0.03), LULU: 46.65 (+1.05), AGN: 211.82 (-0.77), MACK: 8.89 (+0.17), WHR: 181.51 (+1.62), UA: 70.15 (-0.33), DSX: 7.79 (+0.07), ALNY: 89.64 (+0.07), MPC: 95.38 (+1.58), JCP: 7.32 (+0.11), SHW: 240.82 (-0.03), MBLY: 45.69 (-1.06), REGN: 416.65 (+1.40), BHI: 64.23 (+0.72)
SmarTrend Watching for Potential Pullback in Shares of Regeneron Pharmaceuticals After 1.13% Gain
Comtex SmarTrend(R) - Mon Nov 17, 4:43PM CST
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $395.20 to a high of $408.29. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $402.87 on volume of 885,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 416.65 (+1.40)
Regeneron Pharmaceuticals Earnings Hindsight: Up 6.1% in Last 13 Days (REGN)
Comtex SmarTrend(R) - Mon Nov 17, 1:39PM CST
13 days ago, on November 4th, 2014, Regeneron Pharmaceuticals (NASDAQ:REGN) reported its earnings. Analysts, on average, expected earnings of $2.57 per share on sales of $733.3 million. The company actually reported EPS of $2.52 on sales of $725.8 million, missing EPS estimates by $0.05 and missing revenue estimates by $7.5 million. Shares of Regeneron Pharmaceuticals have climbed from $372.39 to $395.20, representing a gain of 6.1% since the company reported earnings 13 days ago.
REGN: 416.65 (+1.40)
Merck Drug Works: Vytorin Study Proves Successful
at Investor's Business Daily - Mon Nov 17, 12:35PM CST
Merck (MRK) cholesterol drug Vytorin, an ezetimibe-simvastatin combo, successfully cuts the risk of heart attacks and strokes in high-risk patients more than simvastatin alone, said the drugmaker in its nearly decade-long, 18,144-patient study. "In...
PFE: 30.45 (+0.01), MRK: 59.29 (-0.35), AMGN: 164.11 (+1.47), REGN: 416.65 (+1.40)
Why Novartis and Regeneron Care About This Tiny Biotech Stock
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 14, 2:00PM CST
Source: Flickr user Ali T It may seem a bit odd to think that drug giants Novartis and Regeneron are paying attention to the far smaller Ophthotech Corp . After all, big companies like these tend to acquire small companies or...
OPHT: 40.54 (+0.44), REGN: 416.65 (+1.40), NVS: 95.43 (-0.30)
Biotech off today led by Biogen
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:00AM CST
BIIB: 301.83 (-1.78), VRTX: 110.48 (-2.32), GILD: 102.55 (+0.21), ALXN: 192.95 (+0.99), AMGN: 164.11 (+1.47), IBB: 295.41 (+1.20), REGN: 416.65 (+1.40), CELG: 107.74 (+0.76)
Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences
Alexander J. Poulos - Seeking Alpha - Fri Nov 14, 8:23AM CST
It is not often for one to come across such an explosive growth company such as Gilead Sciences (NASDAQ: GILD ). By virtue of its stronghold on the Hepatitis C market (HCV) combined with its dominant share in the HIV market, GILD has many...
GILD: 102.55 (+0.21), AMGN: 164.11 (+1.47), SNY: 47.00 (-1.09), REGN: 416.65 (+1.40)
REGN Recent Posts: http://investorshangout.com/Regeneron-Pharmac...EGN-55275/
REGN Regeneron Pharmaceuticals Recent Headline News
Sanofi's Bullish Pipeline Forecast Underwhelms Street
at Investor's Business Daily - 2 mins ago
French big pharma Sanofi laid out its seven-year plan for drug launches, which it says will bring in a cumulative 30 billion euros ($37.6 billion) in their first five years of sales. But Sanofi stock slipped 3% in early trading on the stock market...
NVO: 44.44 (-0.30), MRK: 59.29 (-0.35), LLY: 66.95 (-0.26), SNY: 47.00 (-1.09), REGN: 416.65 (+1.40)
Dupilumab tagged a Breakthrough Therapy for atopic dermatitis
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 7:16AM CST
SNY: 47.00 (-1.09), REGN: 416.65 (+1.40)
Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis
PR Newswire - Thu Nov 20, 12:30AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to dupilumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who are not adequately controlled with topical prescription therapy and/or for whom these treatments are not appropriate. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response. The designation is based on positive results from Phase 1 and 2 clinical trials.
SAN: 8.30 (-0.15), SNY: 47.00 (-1.09), REGN: 416.65 (+1.40)
Regeneron/Bayer's Eylea Gets Japanese Approval for DME - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 3:30PM CST
Regeneron (REGN) announced that the HealthCare segment of Bayer received Japanese approval for Eylea for the treatment of diabetic macular edema.
BIIB: 301.83 (-1.78), AMAG: 35.29 (+0.13), REGN: 416.65 (+1.40)
Positive clinical trial results for alirocumab presented at AHA meeting
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 11:35AM CST
AMGN: 164.11 (+1.47), SNY: 47.00 (-1.09), REGN: 416.65 (+1.40)
Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 10:23AM CST
Regulatory updates from Gilead (GILD) and Regeneron (REGN) and Geron's (GERN) deal with J&J were the highlights last week in the biotech sector.
GILD: 102.55 (+0.21), GERN: 3.18 (+0.07), CLDX: 20.94 (+2.21), CYTR: 2.56 (-0.07), AMGN: 164.11 (+1.47), ABBV: 65.45 (-0.05), REGN: 416.65 (+1.40)
Sanofi and Regeneron Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol
PR Newswire - Wed Nov 19, 7:15AM CST
Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new detailed positive results from six Phase 3 ODYSSEY trials that showed alirocumab significantly reduced low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol). Alirocumab is an investigational fully human monoclonal antibody targeting the protein PCSK9 (proprotein convertase subtilisin/kexin type 9) that is being evaluated for its ability to lower LDL-C.
SAN: 8.30 (-0.15), SNY: 47.00 (-1.09), REGN: 416.65 (+1.40)
Regeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol
PR Newswire - Wed Nov 19, 7:15AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced new detailed positive results from six Phase 3 ODYSSEY trials that showed alirocumab significantly reduced low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol). Alirocumab is an investigational fully human monoclonal antibody targeting the protein PCSK9 (proprotein convertase subtilisin/kexin type 9) that is being evaluated for its ability to lower LDL-C.
SAN: 8.30 (-0.15), SNY: 47.00 (-1.09), REGN: 416.65 (+1.40)
Merck IMPROVEs-IT Causing These Biotechs' Stock Prices to Improve Too
Brian Orelli, The Motley Fool - Motley Fool - Tue Nov 18, 3:00PM CST
Pop quiz: Which one of these drug companies released major positive clinical trial data yesterday? Company Intraday Increase Monday from Friday's Close Merck 1.4% Regeneron Pharmaceuticals 3.3% ...
ESPR: 29.12 (-1.65), MRK: 59.29 (-0.35), REGN: 416.65 (+1.40)
Eylea expands label in Japan
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 8:32AM CST
SNY: 47.00 (-1.09), REGN: 416.65 (+1.40)
Cramer's Mad Money - Globalstar Defends Itself (11/17/14)
SA Editor Miriam Metzinger - Seeking Alpha - Tue Nov 18, 5:37AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday November 17. CEO Interview Jay Monroe, Globalstar (NYSEMKT: GSAT ) Jay Monroe, CEO of Globalstar ( GSAT ) appeared on Mad Money to defend the company...
CST: 43.23 (+0.09), WHR: 181.51 (+1.62), MPC: 95.38 (+1.58), HAL: 49.14 (+0.71), TSN: 43.22 (+0.04), SHW: 240.82 (-0.03), GSAT: 2.64 (-0.03), REGN: 416.65 (+1.40), LULU: 46.65 (+1.05), BHI: 64.23 (+0.72)
Jim Cramer's Top Stock Picks: REGN CST MPC LULU
at The Street - Tue Nov 18, 5:00AM CST
Lululemon is worth a second look now and CST Brands would be a perfect fit for a refiner like Marathon Petroleum.
CST: 43.23 (+0.09), MPC: 95.38 (+1.58), REGN: 416.65 (+1.40), LULU: 46.65 (+1.05)
Regeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Diabetic Macular Edema (DME) in Japan
PR Newswire - Tue Nov 18, 2:05AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for EYLEA® (aflibercept) Injection for diabetic macular edema (DME).
REGN: 416.65 (+1.40)
Jim Cramer's 'Mad Money' Recap: When Bad News Is Really Good News for Us
at The Street - Mon Nov 17, 7:09PM CST
Cramer says this morning's losses and afternoon's gains prove that not all markets need to trade in tandem.
CST: 43.23 (+0.09), BIIB: 301.83 (-1.78), GE: 26.94 (+0.02), NKE: 97.42 (+0.47), HAL: 49.14 (+0.71), TSN: 43.22 (+0.04), GSAT: 2.64 (-0.03), LULU: 46.65 (+1.05), AGN: 211.82 (-0.77), MACK: 8.89 (+0.17), WHR: 181.51 (+1.62), UA: 70.15 (-0.33), DSX: 7.79 (+0.07), ALNY: 89.64 (+0.07), MPC: 95.38 (+1.58), JCP: 7.32 (+0.11), SHW: 240.82 (-0.03), MBLY: 45.69 (-1.06), REGN: 416.65 (+1.40), BHI: 64.23 (+0.72)
SmarTrend Watching for Potential Pullback in Shares of Regeneron Pharmaceuticals After 1.13% Gain
Comtex SmarTrend(R) - Mon Nov 17, 4:43PM CST
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $395.20 to a high of $408.29. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $402.87 on volume of 885,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 416.65 (+1.40)
Regeneron Pharmaceuticals Earnings Hindsight: Up 6.1% in Last 13 Days (REGN)
Comtex SmarTrend(R) - Mon Nov 17, 1:39PM CST
13 days ago, on November 4th, 2014, Regeneron Pharmaceuticals (NASDAQ:REGN) reported its earnings. Analysts, on average, expected earnings of $2.57 per share on sales of $733.3 million. The company actually reported EPS of $2.52 on sales of $725.8 million, missing EPS estimates by $0.05 and missing revenue estimates by $7.5 million. Shares of Regeneron Pharmaceuticals have climbed from $372.39 to $395.20, representing a gain of 6.1% since the company reported earnings 13 days ago.
REGN: 416.65 (+1.40)
Merck Drug Works: Vytorin Study Proves Successful
at Investor's Business Daily - Mon Nov 17, 12:35PM CST
Merck (MRK) cholesterol drug Vytorin, an ezetimibe-simvastatin combo, successfully cuts the risk of heart attacks and strokes in high-risk patients more than simvastatin alone, said the drugmaker in its nearly decade-long, 18,144-patient study. "In...
PFE: 30.45 (+0.01), MRK: 59.29 (-0.35), AMGN: 164.11 (+1.47), REGN: 416.65 (+1.40)
Why Novartis and Regeneron Care About This Tiny Biotech Stock
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 14, 2:00PM CST
Source: Flickr user Ali T It may seem a bit odd to think that drug giants Novartis and Regeneron are paying attention to the far smaller Ophthotech Corp . After all, big companies like these tend to acquire small companies or...
OPHT: 40.54 (+0.44), REGN: 416.65 (+1.40), NVS: 95.43 (-0.30)
Biotech off today led by Biogen
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:00AM CST
BIIB: 301.83 (-1.78), VRTX: 110.48 (-2.32), GILD: 102.55 (+0.21), ALXN: 192.95 (+0.99), AMGN: 164.11 (+1.47), IBB: 295.41 (+1.20), REGN: 416.65 (+1.40), CELG: 107.74 (+0.76)
Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences
Alexander J. Poulos - Seeking Alpha - Fri Nov 14, 8:23AM CST
It is not often for one to come across such an explosive growth company such as Gilead Sciences (NASDAQ: GILD ). By virtue of its stronghold on the Hepatitis C market (HCV) combined with its dominant share in the HIV market, GILD has many...
GILD: 102.55 (+0.21), AMGN: 164.11 (+1.47), SNY: 47.00 (-1.09), REGN: 416.65 (+1.40)
